Humanigen Reports First Quarter 2022 Financial Results
SHORT HILLS, N.J.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab (LENZ), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.
Read the entire artilcle: https://www.businesswire.com/news/home/20220505005996/en/Humanigen-Reports-First-Quarter-2022-Financial-Results